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Functional analysisThe completion of the human genome sequence in 2003 clearly marked the beginning of a new era for biomed-
ical research. It spurred technological progress that was unprecedented in the life sciences, including the devel-
opment of high-throughput technologies to detect genetic variation and gene expression. The study of genetics
has become “big data science”. One of the current goals of genetic research is to use genomic information to fur-
ther our understanding of common complex diseases. An essential ﬁrst step made towards this goal was by the
identiﬁcation of thousands of single nucleotide polymorphisms showing robust associationwith hundreds of dif-
ferent traits and diseases. As insight into common genetic variation has expanded enormously and the technol-
ogy to identify more rare variation has become available, we can utilize these advances to gain a better
understanding of disease etiology. This will lead to developments in personalized medicine and P4 healthcare.
Here, we review some of the historical events and perspectives before and after the completion of the human ge-
nome sequence.We also describe the success of large-scale genetic association studies and how these are expect-
ed to yieldmore insight into complex disorders.We show howwe can now combine gene-oriented research and
systems-based approaches to develop more complex models to help explain the etiology of common diseases.
This article is part of a Special Issue entitled: From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The main aim of the Human Genome Project was to provide a com-
plete and accurate sequence of the 3 billion DNA base pairs that make
up the human genome, aiding a better understanding of the biology of
man. With the completion of the human genome sequence, many in-
sights have been obtained into the genetic variation among individuals
and the genetic architecture of common complexdiseases. Complex dis-
eases are those that are caused by a combination ofmultiple genetic and
environmental factors; they include cardiovascular disease (CVD), type
2 diabetes, autoimmune diseases, cancer and Alzheimer's disease. These
diseases place an enormous burden on modern societies, particularly
with an aging population. Much of our medical care in the future is ex-
pected to deal with these common complex diseases. However, the pre-
vention and treatment of these diseases are still largely ineffective and
their management does not take sufﬁcient account of personal factors,
such as genetic background and environmental conditions. In addition,
these common complex disorders are often treated as if theyweremore
simple disorders that are caused by one or a few risk factors. Fornome to Function.
r Genetics, University Medical
Groningen, The Netherlands.instance, high plasma cholesterol level is considered as a risk factor for
CVD. To reduce CVD risk, the most common drugs being prescribed
are statins, which lower plasma cholesterol. Despite the success of
statins in reducing CVD risk, a considerable number of problems remain
unsolved [1]. A standardized treatment does not work in all patients.
Thus, to develop personalized medicine, it is essential to have a better
estimation of an individual's susceptibility to diseases based on his/her
personal genetic and environmental factors and to decide on the most
effective intervention steps for disease prevention and treatment. This
concept represents “P4 healthcare”, which stands for a predictive, pre-
ventive, personalized and participatory healthcare system [2].
Before the completion of the Human Genome Project, progress in
understanding complex disorders was slow and particularly the insight
into their causes and mechanisms remained limited. Complex diseases
often show a non-Mendelian inheritance pattern due to the interaction
ofmultiple factors. Despite the success in studyingMendelian disorders,
family-based linkage analysis showed little power and low resolution in
identifying risk genes for complex diseases, often yielding inconsistent
or ambiguous linkage signals that cannot be validated [3]. The comple-
tion of the human genome sequence has revealed millions of genetic
variants in the human genome. This has generated an unprecedented
explosion of innovative analysis techniques that can take full advantage
of the full sequence data and the corresponding functionality of the ge-
nome. As a result, genome-wide association studies (in which the fre-
quency of genetic variants is compared between patients and healthy
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lying complex diseases. This reviewwill highlight some of the steps that
were needed to reach this point and will describe the success of the
large-scale genetic association studies. It will show how the results
from these studies are expected to contribute to insights into complex
disorders that will help drive P4 healthcare.
2. Historic perspective
Whatwas known before thehumangenome sequencewas complet-
ed? In a landmark paper in 1979 [4], Jeffreys described the ﬁrst DNA se-
quence polymorphisms and estimated their occurrence throughout the
genome at a frequency of approximately 1:100 nucleotides. This ﬁnding
led rapidly to the realization that this genetic information could be de-
ployed to generate a complete genetic linkage map of the human ge-
nome [5]. This led to the mapping of inherited diseases (with the aim
of identifying the disease-causing genes), the determination of genetic
defects and the development of genetic counseling. Indeed, by the
mid-1990s, most Mendelian disorders had been mapped and deﬁned,
including the identiﬁcation of the locus for Huntington's disease, and
the cloning of the genes for Duchennemuscular dystrophy and for cystic
ﬁbrosis.
Whereas theMendelian disorders were initially revealed using link-
age analysis in affected families followed by positional cloning strate-
gies, the complex diseases were much harder to comprehend due to
their non-Mendelian inheritance pattern. For example, the identiﬁca-
tion of genes deﬁning type 2 diabetes and dyslipidemias initially relied
on strategies based on candidate gene sequencing [6]. As the function
of only 1% of man's ~22,000 genes was known in the 1990s, it was high-
ly unlikely that the candidate gene strategywould be successful. Never-
theless, in the lipidﬁeld,manymutationswere discovered in geneswith
known functions in lipid metabolism by sequencing cohorts of patients
and controls (e.g. LDLR, APOE, APOB, LPL). Some genes were found by
linkage analysis in the families that are affected by rare forms of diabe-
tes, such as inmature onset of diabetes of the young (MODY). However,
the mutations in such genes are relatively rare and do not explain the
majority of patients with metabolic abnormalities or those suffering
from common type 2 diabetes.
Potential disease genes were also widely deployed when using the
candidate gene approaches to study a common disease. Several poten-
tial functional polymorphisms were frequently tested in genetic associ-
ation studies using a case–control design. These studies were done on a
gene-by-genebasis andwere therefore extremely laborious. Despite the
limited designs of these early studies, some of the gene polymorphisms
showed very robust effects and were replicated successfully in many
subsequent studies. These include the APOE polymorphisms that were
associated with dyslipidemias [7] and Alzheimer's disease [8], while
polymorphisms of PPARgamma were robustly associated with the
risk of developing type 2 diabetes [9]. However, in many other studies,
the use of relatively small cohorts (often fewer than 1000 cases) and
the lack of sufﬁcient knowledge of the human genome and of gene
functions resulted in many spurious observations that could not be
replicated.
Thus, prior to the complete sequencing of thewhole human genome
in 2003, only the speciﬁc regions of human genome (referred as loci),
genes and mutations for most of the Mendelian diseases that segregate
in large families had been discovered. Linkage analysis had had some
success in linking candidate genes to complex diseases; it was particu-
larly successful when focusing on some extreme and rare cases that re-
sembled Mendelian disorders. But new methods and techniques were
needed to understand the genetic basis of common complex diseases.
3. Completing the human genome sequence
The need to determine the whole human genome sequence was
foreseen by the end of the 1980s, when the Human Genome Projectwas boldly proposed to initiate a massive, international, sequencing ef-
fort. The initial steps included generating the complete linkagemap [10]
and cloning the human genome using yeast and bacterial artiﬁcial chro-
mosomes [11]. These formed the basis for sequencing the human ge-
nome, which was essentially completed after 30 years of effort and
using automatedmachines based on shotgun Sanger sequencing strate-
gies. Two landmark papers in 2001 [12,13] described the initial se-
quence of the human genome. At that time, the number of genes was
estimated to be around 30,000–40,000. This number was subsequently
adjusted to ~22,000 genes, which ismuch less than originally calculated
largely because most genes appear in different alternative splice forms,
whichmade a proper estimate very hard. In shotgun Sanger sequencing,
the DNA fragments of 200 kb or longer are ﬁrst cloned into appropriate
bacterial and yeast vectors. The clones are then sequenced and produce
reads of some 300 bases in length. The main challenge in shotgun se-
quencing is to assemble these short reads in the correct order and to
form a contiguous sequence for each of the chromosomes. Thus, the
cloned DNA fragments must have a high overlap and redundancy in
order to generate a contiguous sequence with more than 99% accuracy.
This greatly limits the sequencing efﬁciency. From 2005, the develop-
ment of new, next-generation sequencing (NGS) technologies, which
were not based on Sanger sequencing and cloning, greatly facilitated
the fast sequencing of DNA [14,15]. Currently, the most popular NGS
technologies include the Roche 454 [16] and Illumina sequencing
platforms [17]. The principle underlying both technologies lies in
sequencing-by-synthesis, usingpyrosequencing (Roche 454) orﬂuores-
cent labeling of nucleotides (Illumina). Their huge advantage is their
high-throughput capacity: they can sequence 30–60 million reads per
run, thus increasing throughput many hundred-fold over Sanger se-
quencing techniques. These NGS technologies are also referred to as
deep sequencing.
With the advent of NGS, we have witnessed a dramatic drop in the
cost of sequencing and the accompanying exponential growth in the
amount of sequence data generated in large numbers of individuals.
The data have revealed many genetic differences between individuals,
referred as genetic variation. Single nucleotide polymorphisms (SNPs)
are one of the most studied types of genetic variation. The initial
draft sequence from the HGP identiﬁed around 1.4 million SNPs in
2000, while now more than 50 million SNPs have been identiﬁed
and this number is expected to increase further as more genomes are
sequenced. These SNPs show the different frequencies in human
population. Some SNPs can be common (with a minor allele frequency
MAF ≥ 5%), whereas some SNPs have a low frequency (1% ≤ MAF b
5%) or are rare (MAF b 1%).
The spectrum of genetic variation in human population is shaped by
the age of genetic mutations, natural selection, and random genetic
drift. During the DNA replication procedure, some random mistakes
can occur. These mistakes in genetics are called mutations and the al-
tered nuclear acids are called alleles. The mutation rate was estimated
to range from 1.1 to 3 × 10−8 per base per generation [18,19], and a re-
cent analysis has shown thatmutation rates can be higher inmales than
in females and that this effect increases with paternal age [20]. As these
mutations are transmitted to the following generations, they become
more andmore frequent in a population over time, unless there is a sub-
sequent loss of alleles from the population by natural selection or ran-
dom genetic drift. This may lead to some alleles showing a lower
frequency in human populations than anticipated based on the age of
the mutations.
The alleles of different SNPs that near each other on the same chro-
mosome can show non-random combinations. If you observe one spe-
ciﬁc allele at the ﬁrst SNP position, you are more likely to observe
another speciﬁc allele at the second SNP position than anticipated by
chance. It is because these SNPs mostly remain linked during the chro-
mosomal recombination at meiosis and travel together between gener-
ations. This phenomenon is called linkage disequilibrium and the region
with such linked SNPs is called a “haplotype” block. This formed the
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this project, SNPs were identiﬁed in large pedigrees to obtain phase in-
formation aboutwhich SNPs travel together over generations. Typically,
the haplotype blocks present relatively short segments of DNA, up to
200–300 kb. The identiﬁcation of these haplotype blocks can have an
important implication in genetic analysis. It would be extremely expen-
sive to directly genotype millions of SNPs. Since some SNPs form haplo-
type blocks, tagging SNPs (tagSNPs) could be identiﬁed to serve as a
marker for a particular haplotype. These tagSNPs form the core set of
500,000 markers that is normally used on a DNA chip for detecting ge-
notypes. In addition, imputation algorithms have been developed to
predict the genotype of a SNP based on the known genotype of a SNP
or SNPs in the same haplotype. In this way, it is possible to predict the
genotypes for ~100 million SNPs, based on the genotype information
of a limited set of tagSNPs (500,000) and the information on linkage dis-
equilibrium. Imputation strategies have become more and more accu-
rate since whole genome sequencing (WGS) has been performed in
large numbers of samples.WGS has permitted the construction of refer-
ence genomes and haplotypes, for example, the 1000 Genomes project
[22] and the Genome of the Netherlands (Go-NL) project [23]. In partic-
ular, WGS can now capture low-frequency variants more accurately. As
a result, genotyping on a genome-wide scale has become not only af-
fordable but also highly informative; it has completely changed the
ﬁeld of human genetics over the past ten years.
4. Genome-wide association studies
Analyses using genome-wide association studies (GWAS) represent
one of the most important advances in genetics that emerged from the
complete human genome sequence and the availability of affordable
DNA chips and accurate imputation algorithms. These analyses compare
allele frequencies between patients and controls. If a speciﬁc allele of
one SNP shows a higher frequency in patients than in controls, the
SNP is determined to be associatedwith that disease and the speciﬁc al-
lele is the risk allele for that disease. The strategy is based on the com-
mon variant–common disease hypothesis, which states that common
genetic variation must play a major role in common diseases [24–26].
The ﬁrst large-scale GWAS were published by the Wellcome Trust
Case–Control Consortium in 2007: they performed a chip-based SNP
study on 17,000 individuals, testing association between seven diseases
and 469,557 SNPs [27]. Now GWAS have been applied to hundreds
of different diseases and phenotypes. At present, more than 12,000
disease-associated SNPs have been established; they are spread
throughout the human genome (see the Catalog of Published
Genome-Wide Association Studies at https://www.genome.gov/
26525384). Follow-up replications have shown that most of these asso-
ciations are robust [28,29]. Nevertheless, the effect size of each SNP is
quite moderate, and odd ratios are rarely N1.2. However, when all the
SNPs associated with a certain disease are combined, they can explain
a substantial proportion of the heritability for that disease. For instance,
40 loci have now been established for celiac disease, explaining up to
53.7% of its heritability [30]. Some SNPs also show association with
more than one disease, for example, SNPs associatedwith several differ-
ent autoimmune diseases are either shared and/or function in the same
molecular pathways, providing more insight into the disease etiology
[31,32].
Despite the great success of GWAS in identifying common genetic
variants associated with complex diseases, the translation of these ﬁnd-
ings into clinical applications is still limited. There are three main rea-
sons why this translation to the clinic is proving difﬁcult. First, a large
proportion of the heritability for most complex diseases is still unex-
plained. This implies that the identiﬁed SNPs are not the whole answer.
Much effort is beingmade to close the “heritability gap”; it might be ex-
plained by unknown epistatic mechanisms, and/or rare variants with
strong effects, and/or a large number of common SNPs with very weak
effects [33]. GWAS with the current sample sizes (thousands to tens ofthousands individuals) are still often underpowered to detect these
effects. Second, there is a lack of functional characterization of disease-
associated SNPs. For the majority of disease-associated loci, it is still dif-
ﬁcult to identify the causal genetic defect. So far, most reported genes
that map close to the association signal have no obvious functional con-
nection to the associated diseases. As the associated SNPmay tag up to a
hundred other SNPs at the same haplotype block (which can harbor
several candidate genes), much work needs to be done to identify the
true causal gene. Third, not all SNPs fall into groups with the tagSNPs
that co-occur on a speciﬁc haplotype background. The causal variants
might show very low linkage to the tagSNPs. Thus, if these SNPs are
not genotyped directly, they cannot be imputed based on the tagSNPs,
nor is it possible to test them systematically in GWAS. We therefore
need to have an intensive genotyping and novel methods to impute
these SNPs using very much larger cohorts.
5. Identiﬁcation of disease-predisposing variants
To translate the association signals to disease etiology for clinic appli-
cations, the ﬁrst important step is to identify the causal, disease-
predisposing variants. The associated SNP serves as a proxy for the causal
variant and is itself not necessarily the causal one. One strategy is to ﬁne-
map the association signal by intensively genotyping the common and
rare SNPs at the associated regions. This approach has been successfully
used to analyze SNPs that associate with celiac disease by employing the
Immunochip, which contains high-density SNPs at immune-associated
loci, including rare variants [30]. The size of the associated lociwas great-
ly reduced and most of them contained only one candidate gene.
The second strategy is to investigate the downstream effect of SNPs.
For instance, the SNPs that alter the protein coding are likely to be func-
tional. Much effort went into sequencing the complete exome (the part
of the genome formed by exons) in order to identify the causal coding
variants. However, this strategy has proved largely unsuccessful [34].
Another possibility being givenmuch attention is that the causal genetic
variants are present in the non-coding regions, which do not alter pro-
tein coding but play a regulatory role [35]. For instance, they inﬂuence
promoter activity and alter the expression level of a certain transcript,
hence producing disease. The transcript can be either protein-coding
(i.e. translated into a protein) [36] or non-coding, like microRNA
(miRNAs) or long non-coding RNA (lncRNAs), which can play a regula-
tory role in biological processes [37,38]. Interestingly, it has been ob-
served that disease-associated SNPs are more likely to have an effect
on gene expression than randomly chosen SNPs [39–42]. In most
cases, SNPs exert a similar effect in different cell- or tissue types, but
some of them may affect a transcript in only one speciﬁc cell- or tissue
type. It is estimated that approximately 30–60% of SNPs show a tissue-
speciﬁc effect on transcripts [43–45]. Thus, when a SNP at a disease-
associated locus shows an effect on the level of one or more transcripts,
especially in disease-relevant cell- or tissue types, this SNP is likely to be
(or very close to) a causal variant. This approach is beingwidely used to
pinpoint the causal variant and genes for disease association. For exam-
ple, it has successfully identiﬁed the causal effect of a non-coding vari-
ant at the 1p13 cholesterol locus. This non-coding variant is located at
the binding site of a transcription factor and it affects the expression
level of the SORT1 gene speciﬁcally in the liver [46].
In conclusion, linking speciﬁc functions and mechanisms to the
disease-associated loci is a very important step. Fine mapping may be
required and subsequent steps could directly identify a downstream
functional effect. From there, we can either zoom in on the predisposing
genetic variant or focus on the SNPs that alter protein coding or show a
regulatory effect.
6. Functional analysis of candidate genes
Understanding disease mechanisms requires the identiﬁcation of
causal variants and causal genes as well as functional analysis. Since
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genetic variants, pinpointing the closest gene as the candidate gene
can sometimes yieldmisleading results. However, one successful exam-
ple of functional analysis is a recentwork on the obesity-associated var-
iants at the FTO (fat mass and obesity associated) gene [47]. Since 2007,
a variant at theﬁrst intron of the FTOhas been known to show the stron-
gest association with obesity in humans [48]. Since then, tremendous
efforts have beenmade to try and understand the role of FTO in obesity
[49], but no functional connection had beendiscovered. In 2014, Smemo
et al. reported that the FTO genetic variant acts as a long-range enhancer
using chromatin interaction analysis, affecting the expression of the
IRX3 gene at a distance of 1.2 mb (Fig. 1) [47]. IRX3 is thus likely to be
the true causal gene rather than FTO. Further experiments revealed
that Irx3-deﬁcientmice showed a 25–30% reduction in bodyweight, es-
pecially when on a high-fat diet. This study nicely demonstrates the
multiple steps needed tomove frompinpointing a genetic variant to un-
derstanding its functionality, including how identifying the causal vari-
ant can lead to a better understanding of the gene–environment
interaction (Fig. 1).
Once candidate genes have been identiﬁed, there are many strate-
gies to study the possible disease mechanisms, for example, cellular
models and in vivo models (ranging from yeast and Caenorhabditis
elegans tomammalianmodels in rodents andprimates) [50–52]. A com-
prehensive discussion of the possible choices would depend on the dis-
ease area and the scientiﬁc questions, for instance, there is much
interest for studying cardiac development in zebraﬁsh [53,54]. But if a
gene with exceptionally strong evolutionary conservation needs to be
interrogated and the precise disease phenotype is not important,
C. elegans or Drosophilamaybe the model of choice, as studies in these
lower animals can be performed efﬁciently.
The mouse is, however, the most widely used and versatile animal
model. Most human diseases can be studied in the mouse, because it
is also a mammal and it has an almost identical gene set to man. Fur-
thermore, mouse models have a good track record in replicating
human genetic diseases when challenged with appropriate environ-
mental stimuli and/or when genetically modiﬁed at a homolog gene.
One example is the SNP mapping close to the TCF7L2 gene, whichFTO
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Fig. 1. Functional analysis of obesity-shows the strongest association with type 2 diabetes. Many studies in
man predicted the gene's function to be a beta-cell controlling insulin
secretion [55,56], but a gene knockout study provided evidence that,
at least in mice, the gene functions in the hepatic glucose metabolism
[57]. More work is needed tomap the causalmutation, ﬁnd further sup-
port that TCF7L2 is the causal gene, and clarify its role in man.
The breakthrough for themouse as amodel for human gene function
and genetic diseases came with the discovery – in the laboratory of
Nobel Prize winner Mario Capecchi – that any gene of interest could
be subject to homolog recombination in embryonic stem cells [58].
This ﬁnding, published in 1988, paved the way to making loss-of-
functionmousemodels,which have beenwidely used ever since. Exam-
ples of well-established mouse models are the knockouts for the APOE
gene for Alzheimer's disease and LDLR for dyslipidemia and CVD [59].
However, knockouts lead to a genetic deﬁciency in the entire animal
and are often lethal. So it was an important reﬁnement when the Cre–
LoxP system was invented, allowing the generation of cell-type-
speciﬁc loss-of-function models [60]. The Cre recombinase can be
expressed in a cell-type-speciﬁc fashion, and the timing can be adjusted
using an appropriate promoter or bymaking use of an induction system.
The Cre–LoxP method is extremely useful in cases where the complete
knockout of the gene cannot be studied due to lethality and it extended
the applicability of the knockout strategy. Hence, the molecular genetic
mouse toolbox has been instrumental in generatingmost of our current
mechanistic insight. A caveat inmousemodels, however, is the difﬁculty
of generating mouse mutants with low gene expression levels, rather
than full gene deﬁciencies. Suchmodels are extremely useful inmimick-
ing the effects of common genetic variation,which is also believed to act
by affecting gene expression levels rather than by silencing them
completely.
In 2013, the CRISPR/Cas systemwas invented and it has proved to be
evenmore versatile for generatingmouse models [61,62]. It is based on
a viral defense system found in bacteria. The CRISPR vector guides the
Cas-cleavage enzyme to a speciﬁc site in the genome, which is then
cleaved and repaired imprecisely. In this way, a series of mutations
can be engineered. This new technique is also very efﬁcient, since the
vectors can be introduced into fertilized oocytes to generate theIRX3
1.2 Mb
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into other animals or cell lines to study their effects in vitro, prior to gen-
erating an animal model. Thus, we now have mature technologies to
modify speciﬁc genes and there are now hardly any barriers to studying
the mechanisms and genotype–phenotype relationships in model sys-
tems of human disease [63].
7. Combining datasets: systems genetics
Functional analysis of candidate genes can conﬁrm which genes are
causally involved in a disease and provide insights into their function.
However, the gene knockout in model organisms does not really
mimic the consequence of the genetic variant in humans. When we
identify a genetic variant that alters protein coding or the expression
level of a certain transcript, the next natural step is to decipher the
further consequences of the altered protein and transcripts. Thus, a
systems-based approach is essential to track the ﬂow of biological
information from DNA → transcripts → proteins → metabolites →
phenotypes [64,65] and analyzes the interaction between the human
genome and environmental factors, including gut microbial composi-
tions [66]. This promising strategy is called systems genetics. By deﬁni-
tion, this approach reveals the ﬂow of genetic variation from genotype
to phenotype, throughmulti-dimensional biomolecules and their inter-
actions [67].
The rapid advancement of high-throughput technologies that allow
the affordable proﬁling of transcripts, proteins, metabolites and even
gut bacterial composition has made this systems approach more and
more attractive in the post-GWAS era. It has been observed that the ef-
fect of genetic variants at intermediate molecular levels can be much
more pronounced than that observed at end-of-point phenotypes
(called “phenotype buffering”) [68]. This implies that genetic variation
can have dramatic effects on gene expression and strong effects on im-
mediate downstream phenotypes, such as lipids [69] or other metabo-
lites [70], while having very weak or no effect on the ﬁnal disease
presentation, like myocardial infarction. For instance, genetic variants
at the FADS1 gene (fatty acid desaturase 1) could explain up to 40% of
the observed variation of phospholipids [71], but they have only a
small or modest effect on several complex diseases, including inﬂam-
matory bowel diseases and metabolic disorders. Therefore, we should
have the power to detect such genetic effects on intermediatemolecules
in reasonably sized samples (e.g. 1000–2000 samples) with genetic
analysis of transcripts and metabolites [36,71,72]. Linking genetic loci
to the changes in speciﬁcmolecules can yield novel insights into the un-
derlying disease etiology. Themolecules that co-associate with diseases
are likely to bemediators between the genotype and phenotypes.More-
over, recent progress of the Encyclopedia of DNA Elements (ENCODE)
project has provided multiple levels of information on DNA sequences,
including the open chromatin region, transcription factor-binding
sites, enhancers and methylated sites [73]. The disease-associated
SNPs are enriched for these functional elements, offering mechanistic
insights into the regulatory role of genetic variants [74].
The clinical translation of knowledge from GWAS results to disease
mechanism would be limited unless the discrete genetic variants and
molecules converge into networks that can graphically describe the re-
lationships among the genetic variants and various molecules and phe-
notypes [75]. Data-driven network construction, combining prior
knowledge from metabolic pathways and protein–protein interactions,
can result in a new and more complete view of the biological network
[76]. Success in network modeling depends heavily on the complete-
ness and quality of datasets, the sample sizes, and the use of proper
mathematical models. With only a limited ﬁnancial budget, experiment
designers have two choices at themoment, depending on their research
questions. One choice is to proﬁle a dataset as deeply as possible on a
limited number of samples, like the ENCODE project or Genome of the
Netherlands project. The other option is to focus on a few dimensional
data and to proﬁle as many samples as possible, for instance, theGenotype-Tissue Expression (GTEx) project focuses on the gene expres-
sion across diverse human tissues [77]. One notable hallmark of net-
work modeling has been its utilization of mathematical models and
computational algorithms for integrating and analyzing large datasets.
Various algorithms and causal inference modeling techniques have
been proposed to establish networks and determine the causal infer-
ence of the underlying molecular pathways from genotype to pheno-
type [78–81]. However, biological systems are complex and no single
method is best suited for every situation. Compared to generating the
data, the computational analysis now demands a major effort. In the
near future, we expect to see the advancement of computational algo-
rithms and mathematical models, pushed by the huge ﬂow of data
now being generated.
In this review we have discussed several steps leading from genetic
association to causal mechanism that are needed to realize P4 health-
care. These steps include the identiﬁcation of disease-predisposing var-
iants, functional analysis on candidate genes, and the systems-based
approach to illustrate the molecular circuitry from genotype to pheno-
type. The established causal variants can be incorporated into risk pre-
diction models, resulting in a better prediction of an individual's
susceptibility for complex diseases than the use of tagSNPs. This infor-
mation can aid a targeted, personalized strategy for disease prevention.
At the same time, functional studies and systems-based analyses will
yield better insights into disease mechanisms and aid the development
of new therapeutic targets. Moreover, there is an increasing evidence
that reveals the genetic basis of drug efﬁcacy in some patients [82,83].
Some rare and common genetic variants can have a large impact on se-
vere drug reactions, the optimal dosage and efﬁcacy. These observations
should stimulate the adoption of a more personalized approach to
healthcare and more patient participation. Within the next decade,
many more outcomes for clinical application can be expected. Thus,
the completion of the human genome sequence and the subsequent
technological advances mean that we can now pave the way to a
broad uptake of P4 healthcare.Acknowledgement
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